Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darenzepine SCHEMBL9629094 | 1.00 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10518957 | 0.85 | KIT (0.48) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL10524643 | 0.79 | NPSR1 (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5879643 | 0.76 | MAPT (0.63) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL5879640 | 0.76 | MAPT (0.63) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL5879639 | 0.76 | MAPT (0.63) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL9629102 | 0.76 | KMT2A (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30685721 | 0.73 | MET (0.66) | MEN1KMT2AKITAURKBKDR | |
| SCHEMBL12143508 | 0.72 | MAPT (0.58) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL10517978 | 0.71 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | disclosed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | Vima Therapeutics, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0538262-A1 | N-DIMETHOXY PHENYL ALKYL-N'-IMIDAZOLYL PHENYL AMIDINE DERIVATIVES AND PROCESS THEREOF | IL YANG PHARM. CO., LTD. (KR) | 1993-04-28 | — | — | EP | disclosed |
| EP-0276735-B1 | AQUEOUS OR WATER-DISPERSABLE POWDERY PREPARATION OF A SLIGHTLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE AGENT, AND PROCESS FOR ITS PRODUCTION | BASF Aktiengesellschaft (DE) | 1992-04-01 | — | — | EP | disclosed |
| WO-1992000966-A1 | N-DIMETHOXY PHENYL ALKYL-N'-IMIDAZOLYL PHENYL AMIDINE DERIVATIVES AND PROCESS THEREOF | IL YANG PHARM. CO., LTD. (KR) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | MEN1 3746/4885KMT2A 847/4885ALDH1A1 2939/4885 |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | CHRM3, CHRM5, CHRM2 | MEN1 3746/4885KMT2A 847/4885ALDH1A1 2939/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | MEN1 2940/4885KMT2A 4541/4885ALDH1A1 1598/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | MEN1 3746/4885KMT2A 847/4885ALDH1A1 2939/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | MEN1 4598/4885KMT2A 791/4885ALDH1A1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.